Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06907875 · ClinicalTrials.gov registry record · Phase 1

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

A Phase 1 study of Facioscapulohumeral Muscular Dystrophy, sponsored by Epicrispr Biotechnologies.

Recruiting
Registry status
Phase 1
Development phase
12
Enrollment target
7
Study locations

NCT06907875 is a Phase 1 study of Facioscapulohumeral Muscular Dystrophy that is actively recruiting participants, run by Epicrispr Biotechnologies. The registered enrollment target is 12 participants, below the 1,510-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (99% lower). The trial reports 7 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06907875, a Phase 1 study of Facioscapulohumeral Muscular Dystrophy, is actively recruiting participants, sponsored by Epicrispr Biotechnologies.

RECRUITING
Registry status
Phase 1
Development phase
12 participants
Enrollment target
7
Study locations

Study Summary

The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.

Conditions Studied

Facioscapulohumeral Muscular Dystrophy

Interventions

  • BIOLOGICAL EPI-321

Study Locations (7)

California

  • David Geffen School of Medicine at University of California, Los Angeles - Los Angeles

Georgia

  • Rare Disease Research - Atlanta

Maryland

  • Kennedy Krieger Institute, Center for Genetic Muscle Disorders - Baltimore

Massachusetts

  • University of Massachusetts Chan Medical School - Worcester

Utah

  • Utah Program for Inherited Neuromuscular Disorders - University of Utah - Salt Lake City

New South Wales

  • Royal Alfred Hospital - Sydney

Other

  • Pacific Clinical Research Network - Auckland

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-05-08
Est. Completion 2032-04-30
Phase Phase 1

Sponsor

Epicrispr Biotechnologies

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06907875

The ClinicalTrials.gov registry entry for NCT06907875 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 6 other Facioscapulohumeral Muscular Dystrophy trials with a reported enrollment target (99% lower). The listed sponsor is Epicrispr Biotechnologies, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Facioscapulohumeral Muscular Dystrophy appearing as the primary indexed condition, and to 1 intervention - of which EPI-321 is the first listed.

NCT06907875 reports 7 study locations spanning 7 distinct geographic areas - top geographies include California, Georgia, Maryland.

Frequently Asked Questions

What is clinical trial NCT06907875 about?

NCT06907875 is a clinical study titled "A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy". The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How s...

What is the current status of trial NCT06907875?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-05-08. Estimated completion is 2032-04-30.

What conditions does trial NCT06907875 study?

This clinical trial studies the following conditions: Facioscapulohumeral Muscular Dystrophy.

What interventions are being tested in trial NCT06907875?

The interventions under investigation include: EPI-321 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06907875?

This trial is sponsored by Epicrispr Biotechnologies, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06907875 being conducted?

This trial has 7 study locations across California, Georgia, Maryland, Massachusetts, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Facioscapulohumeral Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Facioscapulohumeral Muscular Dystrophy

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.